Global edition
Region
NewsWebcastsPodcastsThe Magazine
Sign inSubscribe
Follow Pharma Now@pharmanow.live
Editions & local coverage
United StatesUnited KingdomGermanyFranceItalyIndiaSwitzerlandSingapore

A global knowledge and leadership platform for pharma. We turn complexity into clarity professionals can act on.

Get the Pharma Now app

Read offline, save stories and never miss an edition.

Get it onGoogle PlayDownload on theApp Store
Verticals
  • Microbiology & CCS
  • Pharma IT
  • Pharma Marketing
  • Regulatory Intelligence
  • Bio Pharma
  • Future Pharma Trends
Formats
  • News & Analysis
  • Interviews
  • Webcasts
  • Podcasts
  • Events
  • Magazine
Knowledge Hub
  • Knowledge Hub
  • Research Papers
  • Buyer’s Guides
  • Companies
  • Newsletter Archive
  • Glossary
Company
  • Advisory Board
  • Contributors
  • Write for Us
  • Submit a PR
  • Contact
  • Advertise
Account
  • Subscribe
  • Sign in
  • My Account
Frequently asked

Pharma Now is a leading monthly B2B magazine focused on delivering in-depth content related to the pharmaceutical and biopharma sectors. It covers the latest trends, technological innovations, leadership insights, market developments, and interviews with industry experts.

Pharma Now provides comprehensive coverage, including: - Industry news and updates - Interviews with global pharma leaders - Market insights and trends - Innovations in AI, manufacturing, and pharma operations - Case studies, thought leadership articles, and regulatory updates

Pharma Now caters to a wide range of professionals within the pharmaceutical industry, including C-level executives, R&D professionals, quality managers, regulatory affairs specialists, and business leaders looking to stay informed about global trends and innovations.

You can subscribe to Pharma Now by visiting the Pharma Now website and choosing between print and digital editions.

Yes, Pharma Now welcomes contributions from industry experts. Contributors can submit articles, thought leadership pieces, and case studies. You can register on the contributors' page to submit content and gain recognition for your insights.

Pharma Now offers multiple advertising packages tailored to help companies promote their products, services, and innovations. From full-page ads to special event coverage, advertisers can reach a targeted audience of pharma professionals. For details, visit the Advertise With Us section on the website.

Copyright © 2026 Tantragyan Technologies Pvt Ltd. All Rights Reserved.
Privacy PolicyTerms of UseContact UsAdvertise
Home/News
NewsAI-assisted

Andes Hantavirus Explained: Why the MV Hondius Strain Is Different From Most

The Andes hantavirus strain behind the MV Hondius outbreak is the only known type to spread between humans, with no approved treatment and a fatality rate of 35 to 50 percent.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert (B.Pharm) · Pharma Now
May 08, 20262 min read
Share
Andes Hantavirus Explained: Why the MV Hondius Strain Is Different From Most
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert (B.Pharm) · Pharma Now

Most people have never heard of hantavirus. Fewer still know that one specific strain of it, the Andes virus, now at the centre of the MV Hondius outbreak, is the only type in the world known to spread directly between humans. That single fact is why scientists and health officials are watching this situation so carefully.

The MV Hondius outbreak has been linked to the Andes strain of hantavirus, a rare but potentially severe virus that, in some cases, can spread between humans through close contact, unlike virtually every other hantavirus strain known to science, which only spreads from infected rodents to people. 

The Andes virus is endemic to southern South America, particularly Argentina and Chile. WHO is working on the assumption that the Dutch couple who died were infected before boarding, possibly during a birdwatching trip that took them through Argentina, Chile, and Uruguay, areas where the species of rat known to carry the virus is present. Argentine investigators are now tracing the couple's exact movements across a four-month road trip that began in November 2025.

Once infected, the disease typically begins with fever and gastrointestinal symptoms before rapidly progressing to pneumonia and acute respiratory distress syndrome. In severe cases, it can lead to circulatory shock. Illness onset among MV Hondius patients occurred between April 6 and April 28.

There is no approved antiviral treatment for hantavirus. Critically ill patients require intensive care, including mechanical ventilation in cases of severe respiratory failure. The case fatality rate for Hantavirus Pulmonary Syndrome, the form caused by the Andes strain, has historically been high, ranging from 35 to 50 per cent in documented outbreaks.

Health officials have dismissed comparisons to COVID-19, stressing that hantavirus does not spread through the air like respiratory viruses do and that the risk of a large-scale epidemic is extremely low. Human-to-human transmission of the Andes strain has been documented only in cases involving prolonged, intimate contact, not casual interaction aboard a ship.

Argentina's health ministry reported 101 hantavirus infections in the country since June 2025, roughly double the caseload recorded over the same period the previous year, suggesting that, even before this outbreak, the virus was circulating more actively than usual in South America.

TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert (B.Pharm) · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

Trending now

1

Emcure Pharma Reports 23% Revenue Rise to Rs 2,580 Crore in Q1 FY2026

News · Aug 07, 2026
2

FDA CBER OTP Convenes Town Hall on CMC Readiness Standards for Gene Therapy BLA Submissions

News · Aug 07, 2026
3

FDA Grants Accelerated Approval to Tudriqev for Anti-PD-1 Refractory Advanced Melanoma

News · Aug 07, 2026
4

Global Calcium Pvt. Limited Receives FDA Warning Letter Over Falsified Batch Records and Deleted Electronic Files

News · Aug 07, 2026
5

Global Calcium Secures FDA Warning Letter Closure After Corrective Action Review

News · Aug 07, 2026
The signal
The week in pharma, distilled

One considered email — the stories, moves and numbers that matter, every Friday.

More from Pharma News

All stories →
Emcure Pharma Reports 23% Revenue Rise to Rs 2,580 Crore in Q1 FY2026
News

Emcure Pharma Reports 23% Revenue Rise to Rs 2,580 Crore in Q1 FY2026

Pharma Now Editorial Team · Aug 07, 2026
FDA CBER OTP Convenes Town Hall on CMC Readiness Standards for Gene Therapy BLA Submissions
News

FDA CBER OTP Convenes Town Hall on CMC Readiness Standards for Gene Therapy BLA Submissions

Pharma Now Editorial Team · Aug 07, 2026
FDA Grants Accelerated Approval to Tudriqev for Anti-PD-1 Refractory Advanced Melanoma
News

FDA Grants Accelerated Approval to Tudriqev for Anti-PD-1 Refractory Advanced Melanoma

Pharma Now Editorial Team · Aug 07, 2026